One of Tesla's most fearsome Chinese rivals has just cracked the code to profiting from EVs. Smartphone maker Xiaomi said on Tuesday that its electric vehicle business had turned a quarterly profit for the first time, less than two years after launching its first car.The Apple rival's EV, AI, and other new initiatives division reported a gross profit of $98.5 million for the quarter ending in September. Revenues in the division hit a record high of $4 billion, with 28.3 billion yuan ($3.98 billion) coming ...

Summary of Rigel Pharmaceuticals Conference Call Company Overview - Rigel Pharmaceuticals is a hematology and oncology biotech company focused on expanding its commercial business and pipeline [2][3] Commercial Products - Rigel has three approved products: - **TAVALISSE**: Indicated for immune thrombocytopenia (ITP) with net sales of $44.7 million last quarter, a 70% increase year-over-year [6] - **REZLIDHIA**: Approved for mutant IDH1 relapsed and refractory acute myeloid leukemia (AML) with sales of $8.3 million, a 50% growth from the previous year [6] - **GAVRETO**: Approved for RET fusion positive non-small cell lung cancer and thyroid cancer, with sales increasing from $7 million to $11.1 million [6][12] Financial Performance - Rigel reported $64 million in net product sales last quarter, a 65% increase from the same quarter last year, and $166 million over three months, surpassing total sales for all of 2024 [5] - The company generated $60 million in cash this year and has maintained profitability [4][30] - Guidance for revenue is set at $285-$290 million, with net product sales expected to be $225-$230 million [30] Pipeline Development - Rigel is focused on developing transformational programs, particularly R289 for low-risk myelodysplastic syndromes (MDS) [4][17] - R289 has received fast-track and orphan designations from regulatory agencies, indicating its potential for significant improvement in treatment options [20] - The company plans to initiate a registration study for R289 in 2027 [24] Market Opportunities - The U.S. market for adult chronic ITP has approximately 81,000 patients, with Rigel targeting the second-line treatment population of about 24,000 patients [7] - The market for low-risk MDS is substantial, with current treatments showing limited efficacy, presenting an opportunity for R289 [18][19] Strategic Partnerships - Rigel has partnered with various companies for product distribution, including Grifols in Europe and Kissei in Asia for TAVALISSE [13] - Collaborations with MD Anderson and MyeloMatch are underway to explore additional indications for Olutasidenib and AML treatments [25][27] Future Outlook - Rigel aims to continue in-licensing differentiated assets in hematology and oncology to enhance its portfolio [14][16] - The company is committed to maintaining financial discipline while investing in its pipeline to drive growth [31][32] Key Takeaways - Rigel Pharmaceuticals is experiencing significant growth in its commercial products and is strategically positioning itself for future opportunities in hematology and oncology [5][32] - The focus on developing innovative treatments like R289 and expanding its product offerings through partnerships is central to Rigel's growth strategy [4][14][24]

Key Takeaways SBUX's Q4 operating margin fell 500 bps to 9.4%, driving a 34% EPS drop.Starbucks faces high coffee costs and labor spending that may weigh on early 2026.SBUX expects efficiency efforts and lower G&A to help as U.S. comps show improving trends.Starbucks Corporation (SBUX) reported a solid top-line finish to fiscal 2025, but profitability told a more challenging story.In fourth-quarter fiscal 2025, consolidated operating margin declined 500 basis points year over year to 9.4%, pressured primari ...

With a market cap of $63.8 billion, Autodesk, Inc. (ADSK) is a leading software company specializing in design, engineering, and digital content creation tools. Best known for products like AutoCAD, Revit, Fusion 360, and Maya, the San Francisco-based company serves industries such as architecture, construction, manufacturing, product design, and media/entertainment. Shares of the company have lagged behind the broader market over the past 52 weeks. ADSK stock has increased 2.4% over this time frame, whil ...

FREDERICK, Md., Nov. 17, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global provider of disinfection and decontamination essentials through its premier Binary Ionization Technology® (BIT™) platform, today announced that it has filed a $50 million universal shelf registration statement on Form S-3 with the U.S. Securities and Exchange Commission (“SEC”). Once declared effective, the registration statement will allow TOMI to offer and sell, from time to time, up to an aggrega ...

Banco Santander has had a big year. Give us a sense of how big a year it's been. It's been a great year.Our numbers will be totally on track to deliver all the numbers in our three year plan. And again in 25, we are going to reach our profitability 16 and a half percent. And for shareholders, you know, great value creation, increasing dividend per share, our share price is up 100%, but there's still a lot of inherent value in our stock.Our multiples are still very attractive compared to US banks. For exampl ...

(Photo illustration by Cheng Xin/Getty Images)Getty ImagesZoetis (ZTS) the world’s largest animal-health company, develops and manufactures medicines, vaccines, and diagnostics for both pets and livestock. The stock has come under pressure in recent months as softer clinic traffic, uneven companion-animal demand, and a narrowed full-year outlook weighed on sentiment. Yet the pullback has also driven valuations toward multi-year lows—an unusual reset for a business known for high margins, steady cash generat ...

Core Insights - Ford is addressing production disruptions caused by the Novelis fire and plans to increase F-Series pickup production significantly in 2026, adding over 50,000 units starting in Q1'26 [1][4] Production Plans - At the Dearborn Truck Plant, Ford will introduce a third crew to target an additional 45,000 F-150 units in 2026, reallocating workers from the paused F-150 Lightning plant [2] - The Kentucky Truck Plant will increase assembly line speed by one job per hour, resulting in over 5,000 extra Super Duty trucks annually, alongside hiring more than 100 new workers and investing $60 million in training and upgrades [3][7] Financial Performance - Ford's management highlighted strong demand and firm pricing for full-size pickups during the Q3 earnings call, indicating the importance of the F-Series lineup to overall profitability [4] - Ford's stock has gained 16% over the past three months, underperforming General Motors and outperforming Toyota [5] Valuation Metrics - Ford trades at a forward price-to-sales ratio of 0.33, which is below the industry average, and carries a Value Score of A, compared to General Motors at 0.37 and Toyota at 0.82 [7]

Core Viewpoint - Spectrum Brands exceeded analyst expectations for net income in its fiscal fourth quarter of 2025, leading to a significant increase in stock price despite a decline in net sales [1][2]. Financial Performance - Net sales for the quarter decreased by over 5% year-over-year, totaling $733.5 million, which was below the consensus estimate of over $734 million [2]. - Net income from continuing operations surged more than four times to $53.3 million, with earnings per share rising to $2.61 from $0.97 a year ago, significantly surpassing the expected $0.90 [3]. Business Segments - The company faced substantial disruptions due to government tariffs, particularly affecting imports from China, but managed to achieve sales growth in its Home and Garden segment [4]. - Spectrum Brands anticipates growth in its two highest value businesses, Home and Garden, and Global Pet Care, for the current fiscal year (2026), indicating signs of stabilization in these areas [6].

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 reached $1,400,000,000, with an adjusted EBITDAR margin of 31% and an operating margin of 18%, marking the second best third quarter in the company's history [10][26] - Adjusted EBITDA totaled $442,000,000, reflecting a margin of 31%, which is the second highest third quarter adjusted EBITDA on record [25][26] - Net income was $97,000,000 in Q3, representing a 7% net margin [26] - Total operating expenses increased by 2.5% year over year, primarily due to higher depreciation and amortization from fleet additions [24][25] Business Line Data and Key Metrics Changes - Passenger revenue decreased by 4.9% year over year, but showed a 1.7% improvement compared to Q2 2025 [15] - Domestic passenger unit revenue was flat, while international results were strong with profitability across all regions [16][17] - Premium unit revenue outperformed main cabin by five points year over year, indicating growing demand for premium products and services [19] Market Data and Key Metrics Changes - Domestic performance was impacted by currency, economic, and geopolitical headwinds, particularly in border cities due to changes in U.S. immigration policy [16] - U.S. capacity increased by 15% during the first half of 2025 but was flat for Q3, with expectations of continued improvement in passenger unit revenue [18][22] Company Strategy and Development Direction - The company remains focused on delivering high-quality, sustainable results, strengthening its competitive position, and creating lasting value for shareholders, customers, and employees [14][30] - Investment plans include modernization of the fleet and enhancing customer experience, with the addition of four Boeing 737 MAX aircraft during the quarter [13][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute effectively in a challenging environment, with expectations for sequential improvement in passenger revenue and unit revenue performance in Q4 [22][30] - The company anticipates passenger revenue to increase by 3% to 5% year over year in Q4, supported by favorable industry capacity trends [21][29] Other Important Information - The company reported $934,000,000 in cash on hand, complemented by a $200,000,000 undrawn revolving credit facility, resulting in total liquidity of $1,100,000,000, which accounts for 21% of revenue over the past twelve months [27] - The company is committed to maintaining strong financial flexibility and evaluating opportunities for capital distribution to shareholders in the future [47][30] Q&A Session Summary Question: Guidance on RASM and regional performance - Management expects positive unit revenue on both domestic and international fronts, with strong performance anticipated in the domestic beach portfolio and the U.S. region [33][34] Question: Confidence in U.S.-Mexico resolution - Management is hopeful for a resolution regarding bilateral issues and is in close contact with government officials [36][38] Question: Capacity growth expectations for next year - Management indicated potential for growth in capacity, particularly in the summer IATA season, while not providing specific guidance for 2026 [42][44] Question: Capital allocation and shareholder distribution - Management mentioned strong free cash flow generation and the potential for evaluating additional opportunities for capital distribution to shareholders in the future [46][47] Question: Details on 2024 normalized results - Management clarified that 2024 included nonrecurring items, particularly related to unused tickets and Boeing compensation, which should be considered when comparing results [50][54]